Skip to content

Opus Genetics, Inc.: 10-Q filed 2014-11-12

What Opus Genetics, Inc. reported in its quarterly report filed 2014-11-12 (fiscal Q3 2014): 22 published measures, 60 facts as tagged in accession 0001140361-14-041326.

This filing

Form
10-Q (quarterly report)
Filed
2014-11-12
Fiscal period
fiscal Q3 2014
Accession
0001140361-14-041326 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Opus Genetics, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2014-09-3036,453,456USD
At 2013-12-3119,556,498USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2014-09-307,855,977USD
At 2013-12-316,931,010USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2014-09-3028,597,479USD
At 2013-12-3112,625,488USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2014-09-3014,971,660USD
At 2013-12-3118,688,031USD
At 2013-09-3014,871,000USD
At 2012-12-3113,486,543USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2014-07-01 to 2014-09-30-1,905,448USD92
2014-01-01 to 2014-09-30-16,311,483USD273
2013-07-01 to 2013-09-30-2,140,904USD92
2013-01-01 to 2013-09-30-6,779,759USD273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2014-09-30-89,122,190USD
At 2013-12-31-72,810,707USD

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2014-09-3072,908USD
At 2013-12-3165,172USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2014-01-01 to 2014-09-30424,059USD273
2013-01-01 to 2013-09-30494,037USD273

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2014-07-01 to 2014-09-30-3,141,706USD92
2014-01-01 to 2014-09-30-9,416,736USD273
2013-07-01 to 2013-09-30-1,823,887USD92
2013-01-01 to 2013-09-30-5,646,439USD273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2014-09-3036,343,048USD
At 2013-12-3119,295,196USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2014-07-01 to 2014-09-303,141,706USD92
2014-01-01 to 2014-09-309,416,736USD273
2013-07-01 to 2013-09-301,823,887USD92
2013-01-01 to 2013-09-305,646,439USD273

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2014-07-01 to 2014-09-301,824,740USD92
2014-01-01 to 2014-09-304,797,721USD273
2013-07-01 to 2013-09-30781,281USD92
2013-01-01 to 2013-09-302,258,877USD273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2014-09-30178,253,318shares
At 2013-12-31146,717,795shares

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2014-09-30-42,041USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2014-09-30676,075USD
At 2013-12-31645,921USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2014-09-30603,167USD
At 2013-12-31580,749USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2014-09-30757,503USD
At 2013-12-31507,165USD

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2014-07-01 to 2014-09-30-1,947,489USD92
2014-01-01 to 2014-09-30-16,353,524USD273
2013-07-01 to 2013-09-30-2,140,904USD92
2013-01-01 to 2013-09-30-6,779,759USD273

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2014-07-01 to 2014-09-301,211,842USD92
2014-01-01 to 2014-09-304,327,787USD273
2013-07-01 to 2013-09-30932,762USD92
2013-01-01 to 2013-09-303,001,460USD273

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2014-07-01 to 2014-09-303,744USD92
2014-01-01 to 2014-09-3022,418USD273
2013-07-01 to 2013-09-309,645USD92
2013-01-01 to 2013-09-3028,196USD273

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2014-07-01 to 2014-09-301,236,258USD92
2014-01-01 to 2014-09-30-6,894,747USD273
2013-07-01 to 2013-09-30-317,017USD92
2013-01-01 to 2013-09-30-1,133,320USD273

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2014-01-20 to 2014-01-2120,000,001USD2

Inspect the source

Entity
Opus Genetics, Inc. / CIK 0001228627
Captured
2026-09-20T07:46:24.028Z
SEC response SHA-256
59b3f548361fa5c66fb8bd927bac9bc7dc8822bcce158860c7c4d77974af0a92

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001228627.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))